🇨🇭 Swiss Data Privacy & Precision

Knowledge Hub

How to migrate from legacy EDC systems

A practical, architecture-aware guide to moving off legacy EDC systems without compromising data integrity or regulatory compliance.

Migration & implementation

Why legacy EDC migration is complex

Migrating from a legacy Electronic Data Capture (EDC) system is a complex and risk-sensitive activity within the clinical trial lifecycle.

Legacy systems often support:

  • Ongoing studies
  • Historical clinical trial data
  • Validated workflows
  • Regulatory submissions and inspection records

As a result, organizations must balance modernization efforts with the obligation to preserve data integrity, traceability, and compliance.

Migration complexity is influenced not only by data volume, but also by how systems are structured and interconnected. Migration affects:

  • Clinical data
  • Metadata
  • Audit trails
  • Validation status
  • Downstream system dependencies involving Clinical Trial Management Systems (CTMS) and electronic Trial Master Files (eTMF) platforms

Migrating from legacy clinical systems requires maintaining data integrity, validation continuity, and auditability throughout the transition process.

Common migration risks in legacy clinical trial systems

Legacy EDC migrations introduce several well-known operational and compliance risks. Migration risk increases when systems rely on proprietary data structures or limited export capabilities.

Common migration risks

  • Vendor lock-in: Consolidating multiple systems into a unified platform moves dependency from many vendors to one, which can make a future switch more difficult without contractual data-export and portability guarantees.
  • Data loss or corruption: Clinical data, metadata or queries may be incompletely transferred
  • Audit trail gaps: Historical audit records may become disconnected from migrated data
  • Validation gaps: Evidence demonstrating system validation may become incomplete or inconsistent

Migration approaches for clinical trial systems

Migration strategies vary based on trial status, regulatory timing, data retention requirements, and system architecture. The most common approaches are phased and hybrid migrations.

Phased migration

In a phased migration approach, studies are migrated incrementally rather than all at once. New studies may start on the target platform while legacy systems remain active for ongoing or completed studies.

Key characteristics include:

  • Reduced disruption to active trials
  • Continued use of legacy systems for historical data
  • Parallel operation of multiple EDC environments during transition

This approach reduces immediate operational risk but extends the duration of multi-system management.

Hybrid migration

Hybrid migration combines selective data transfer with controlled coexistence of systems. Active study data may be migrated to the new platform, while certain historical records remain archived in the legacy system.

Hybrid migration requires:

  • Clear definition of authoritative systems of record
  • Documented data lineage across systems
  • Procedures to support inspection readiness across environments
Learn how single database architecture affects migration complexity

Migration complexity in modular eClinical systems

Migration complexity comparison between modular eClinical systems and a unified platform
Migration area Modular eClinical systems Unified platform
Study data migration Requires coordination across EDC, CTMS, and eTMF systems Managed within one shared data environment
Audit trail continuity Historical audit records must be reconstructed across systems Maintained within one unified audit trail
Validation activities Validation must be performed separately for multiple systems Validation framework is centralized
Data lineage Lineage must be correlated across systems and interfaces Preserved within one architecture
Ongoing trial operations Active studies may depend on synchronized downstream systems Operational continuity is maintained within one platform
Long-term maintenance Continued dependency on integrations and synchronization Reduced architectural complexity

Data validation during clinical trial migration

Data validation is a core requirement during EDC migration. Organizations must demonstrate that migrated clinical trial data remains:

  • Complete
  • Accurate
  • Consistent with source records

Validation continuity is essential when migrating regulated clinical trial data.

Validation activities commonly include:

  • Reconciliation of subjects, visits, and queries between systems
  • Verification of derived data and calculations
  • Confirmation that metadata and coding structures are preserved
  • Validation scope should align with migration complexity and regulatory expectations

Maintaining regulatory compliance during migration

Regulatory compliance must be preserved before, during, and after migration. Migration should be treated as a regulated operational change with defined controls, documentation, and oversight.

Requirements may include:

21 CFR Part 11 GDPR ICH-GCP

Compliance complexity increases when audit trails, validation records, and system controls remain distributed across multiple systems.

Key compliance considerations include:

  • Continuous access to complete audit trails
  • Preservation of electronic signatures and approvals
  • Controlled access to migrated and archived records
  • Preservation of inspection-ready documentation

Audit trail continuity must be preserved throughout migration activities.

Change management during EDC migration

EDC migration introduces operational, technical, and organizational changes that require structured management.

Change management helps prevent migration activities from disrupting:

  • Data integrity
  • Regulatory compliance
  • Ongoing trial execution

Effective change management includes:

  • Documented risk assessment and impact analysis
  • Controlled system configuration changes
  • User training and role updates aligned with migration phases

These activities support operational continuity while maintaining regulatory control.

Best practices for legacy EDC migration

EDC migration is most effective when it is treated as a controlled, architecture-level change rather than a purely technical data transfer. A structured, architecture-aware approach helps reduce execution risk, limit disruption to ongoing trials, and address regulatory expectations early in the process.

Successful EDC migrations typically follow established best practices:

  1. 01 Early planning tied to trial milestones and regulatory deadlines
  2. 02 Clear definition of data ownership and system roles
  3. 03 Validation planning aligned with migration scope
  4. 04 Documentation of decisions, assumptions, and controls
  5. 05 Defined governance for archived and migrated records

Migration is not only a technology replacement activity, but a transition from fragmented system coordination toward a unified data architecture.

Summary

Migrating from legacy EDC systems is a technically and operationally complex activity with direct impact on data integrity, validation status, and regulatory compliance.

Legacy environments often contain long-running studies, historical records, and established audit trails, which increases migration sensitivity.

Key takeaway

Risks such as data loss, audit trail discontinuity, validation gaps, and vendor lock-in can be reduced through structured migration planning, rigorous validation, and architecture-aware governance.

Organizations that align migration strategy with regulatory requirements and long-term system architecture goals can reduce operational complexity and establish a more sustainable clinical data foundation for future clinical trials.

Use the evaluation checklist for unified clinical trial platforms

oomnia Platform

Ready to move beyond fragmented systems?

Reading is a good start. Seeing it in action is where it becomes real.

oomnia brings everything together in one unified clinical platform, designed to simplify operations, improve data quality, and give teams full visibility across every stage of a trial

Explore oomnia